清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

替莫唑胺 医学 中期分析 临床终点 人口 放化疗 内科学 肿瘤科 无进展生存期 放射治疗 外科 化疗 临床试验 环境卫生
作者
Roger Stupp,Sophie Taillibert,Andrew A. Kanner,Santosh Kesari,David M. Steinberg,Steven A. Toms,Lynne Patricia Taylor,Frank Scott Lieberman,Antonio Silvani,Karen Fink,Gene H. Barnett,Jay‐Jiguang Zhu,John W. Henson,Herbert H. Engelhard,Thomas C. Chen,David Dinh Tran,Jan Šroubek,Nam Tran,Andreas Felix Hottinger,Joseph C. Landolfi
出处
期刊:JAMA [American Medical Association]
卷期号:314 (23): 2535-2535 被引量:1429
标识
DOI:10.1001/jama.2015.16669
摘要

IMPORTANCE: Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly. OBJECTIVE: To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma. DESIGN, SETTING, AND PARTICIPANTS: After completion of chemoradiotherapy, patients with glioblastoma were randomized (2:1) to receive maintenance treatment with either TTFields plus temozolomide (n = 466) or temozolomide alone (n = 229) (median time from diagnosis to randomization, 3.8 months in both groups). The study enrolled 695 of the planned 700 patients between July 2009 and November 2014 at 83 centers in the United States, Canada, Europe, Israel, and South Korea. The trial was terminated based on the results of this planned interim analysis. INTERVENTIONS: Treatment with TTFields was delivered continuously (>18 hours/day) via 4 transducer arrays placed on the shaved scalp and connected to a portable medical device. Temozolomide (150-200 mg/m2/d) was given for 5 days of each 28-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival in the intent-to-treat population (significance threshold of .01) with overall survival in the per-protocol population (n = 280) as a powered secondary end point (significance threshold of .006). This prespecified interim analysis was to be conducted on the first 315 patients after at least 18 months of follow-up. RESULTS: The interim analysis included 210 patients randomized to TTFields plus temozolomide and 105 randomized to temozolomide alone, and was conducted at a median follow-up of 38 months (range, 18-60 months). Median progression-free survival in the intent-to-treat population was 7.1 months (95% CI, 5.9-8.2 months) in the TTFields plus temozolomide group and 4.0 months (95% CI, 3.3-5.2 months) in the temozolomide alone group (hazard ratio [HR], 0.62 [98.7% CI, 0.43-0.89]; P = .001). Median overall survival in the per-protocol population was 20.5 months (95% CI, 16.7-25.0 months) in the TTFields plus temozolomide group (n = 196) and 15.6 months (95% CI, 13.3-19.1 months) in the temozolomide alone group (n = 84) (HR, 0.64 [99.4% CI, 0.42-0.98]; P = .004). CONCLUSIONS AND RELEVANCE: In this interim analysis of 315 patients with glioblastoma who had completed standard chemoradiation therapy, adding TTFields to maintenance temozolomide chemotherapy significantly prolonged progression-free and overall survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00916409.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼的应助被专注的思松采纳,获得20
刚刚
Galaxy完成签到,获得积分10
35秒前
好运连连关注了科研通微信公众号
48秒前
隐形曼青的应助被科研通管家采纳,获得10
53秒前
ChencanFang完成签到,获得积分10
1分钟前
楚科研完成签到 ,获得积分10
1分钟前
潇洒小海豚完成签到,获得积分10
1分钟前
奔跑的应助被Jianing采纳,获得30
2分钟前
NexusExplorer的应助被11采纳,获得10
2分钟前
姚老表发布了新的文献求助30
2分钟前
2分钟前
乐乐的应助被GraceKabiri759采纳,获得30
3分钟前
3分钟前
好运连连发布了新的文献求助10
3分钟前
3分钟前
3分钟前
Agan发布了新的文献求助10
3分钟前
把饭拼好给你完成签到 ,获得积分10
4分钟前
思源的应助被Agan采纳,获得10
4分钟前
好运连连完成签到,获得积分10
4分钟前
4分钟前
4分钟前
五月完成签到,获得积分10
4分钟前
瘦瘦的枫叶完成签到 ,获得积分10
4分钟前
sugar发布了新的文献求助10
4分钟前
传奇3的应助被wuyy采纳,获得10
5分钟前
酷波er的应助被sugar采纳,获得10
5分钟前
Omarkyarm完成签到,获得积分10
5分钟前
5分钟前
wuyy发布了新的文献求助10
5分钟前
圆月弯刀完成签到 ,获得积分10
5分钟前
合适乐巧完成签到 ,获得积分10
5分钟前
null的应助被mashibeo采纳,获得10
5分钟前
wuyy完成签到,获得积分20
5分钟前
赘婿的应助被wuyy采纳,获得10
5分钟前
6分钟前
wuyy发布了新的文献求助10
6分钟前
JUN完成签到,获得积分10
6分钟前
6分钟前
瞿人雄完成签到,获得积分10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195184
求助须知:如何正确求助?哪些是违规求助? 9580915
关于积分的说明 21872990
捐赠科研通 7795171
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561276
邀请新用户注册赠送积分活动 2484678